Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1994-11

AUTHORS

P. Charbonneau, I. Harding, J. J. Garaud, J. Aubertin, F. Brunet, Y. Domart

ABSTRACT

A prospective, randomized multicentre study was conducted in order to evaluate the potentially superior tolerability profile of teicoplanin plus netilmicin compared with vancomycin plus netilmicin in patients in ICUs. We considered that these glycopeptides have been shown to have comparable efficacy and that comparative tolerability is of paramount importance, particularly in severely ill patients. A total of 56 patients were enrolled into the study (36 males and 20 females). Twenty-four patients were included in the teicoplanin plus netilmicin group (15 males, 9 females: mean age 56.8 years). The mean simplified acute physiological score (SAPS) was 9.4 (range 4–20). Thirty-two patients were randomized to receive vancomycin plus netilmicin (21 males, 11 females; mean age 56.4 years). The mean SAPS was 9.3 (range 2–16). Septicaemia was the most common infection (14 cases in each group). Most infections were caused byStaphylococcus aureus or coagulase-negative staphylococci. The mean daily doses were: for teicoplanin, 457 mg (6.7 mg/kg); for vancomycin, 1678 mg (24.4 mg/kg); and for netilmicin 263.3 mg (3.9 mg/kg) in the teicoplanin group and 248 mg (3.8 mg/kg) in the vancomycin group. The trough levels of teicoplanin in the serum remained mostly between 7 and 10 mg/l, while more fluctuation was seen in patients receiving vancomycin. The mean trough levels of netilmicin in the serum were 1.2 (SD 0.9) mg/l in the teicoplanin group, compared with 1.7 (SD 1.4) mg/l in the vancomycin group (NS:p>0.05). The trough levels of netilmicin in the serum were often higher in the vancomycin group, resulting in decreases in the dose of netilmicin eight times in this group (25% of patients) and once in the teicoplanin group (4.2% of patients). Adjustments to the dose of vancomycin were made in six patients, due to nephrotoxicity or undesirable levels in the serum, but no adjustments to the dose were made in the teicoplanin group (p=0.032). Overall, adjustments to the dose were made to one or both study drugs in 10 patients in the vancomycin group and one in the teicoplanin group (p<0.02). Clinical and bacteriological efficacy was similar: clinical success was achieved in 80% of the patients in the teicoplanin group compared with 83% in the vancomycin group. The bacteriological response rates were 81 and 84%, respectively. Adverse events were reported in 24 patients: 7 (29%) in the teicoplanin group and 17 (53%) in the vancomycin group (p>0.05). Nephrotoxicity was reported as an adverse event in 21 patients: 6 (25%) in the teicoplanin group and 15 (47%) in the vancomycin group (p=0.09). The mean increase in the levels of creatinine in the serum at the end of therapy or up to 1 week after therapy, compared with the baseline, was significantly higher for vancomycin (56.6%), but not teicoplanin (15.3%,p<0.02). Creatinine clearance in the vancomycin group was significantly lower than baseline throughout the study period, while for teicoplanin there was no difference until the third week of treatment, and this improved again during the fourth week. It is concluded that teicoplanin is an efficacious, well-tolerated and convenient antibiotic for the treatment of Gram-positive infection in ICU patients. More... »

PAGES

s35-s42

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01713981

DOI

http://dx.doi.org/10.1007/bf01713981

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027313514

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7699155


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Critical Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross Infection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Monitoring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gram-Positive Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Netilmicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Teicoplanin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vancomycin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service de R\u00e9animation Medicale et de Maladies Infectieuses, University Hospital, Avenue de la C\u00f4te de Nacre, F-14033, Caen, CEDEX, France", 
          "id": "http://www.grid.ac/institutes/grid.411149.8", 
          "name": [
            "Service de R\u00e9animation Medicale et de Maladies Infectieuses, University Hospital, Avenue de la C\u00f4te de Nacre, F-14033, Caen, CEDEX, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Charbonneau", 
        "givenName": "P.", 
        "id": "sg:person.01270350653.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270350653.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thackelay's Ltd, Horton, SN10 3NB, Devizes, Wiltshire, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Thackelay's Ltd, Horton, SN10 3NB, Devizes, Wiltshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harding", 
        "givenName": "I.", 
        "id": "sg:person.01006233511.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006233511.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, New Jersey, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garaud", 
        "givenName": "J. J.", 
        "id": "sg:person.01317726721.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317726721.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital, Bordeaux, France", 
          "id": "http://www.grid.ac/institutes/grid.42399.35", 
          "name": [
            "University Hospital, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aubertin", 
        "givenName": "J.", 
        "id": "sg:person.07631560136.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07631560136.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Cochin, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411784.f", 
          "name": [
            "University Hospital Cochin, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brunet", 
        "givenName": "F.", 
        "id": "sg:person.0741664152.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741664152.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Bichat, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411119.d", 
          "name": [
            "University Hospital Bichat, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Domart", 
        "givenName": "Y.", 
        "id": "sg:person.0610744222.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610744222.10"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1994-11", 
    "datePublishedReg": "1994-11-01", 
    "description": "A prospective, randomized multicentre study was conducted in order to evaluate the potentially superior tolerability profile of teicoplanin plus netilmicin compared with vancomycin plus netilmicin in patients in ICUs. We considered that these glycopeptides have been shown to have comparable efficacy and that comparative tolerability is of paramount importance, particularly in severely ill patients. A total of 56 patients were enrolled into the study (36 males and 20 females). Twenty-four patients were included in the teicoplanin plus netilmicin group (15 males, 9 females: mean age 56.8 years). The mean simplified acute physiological score (SAPS) was 9.4 (range 4\u201320). Thirty-two patients were randomized to receive vancomycin plus netilmicin (21 males, 11 females; mean age 56.4 years). The mean SAPS was 9.3 (range 2\u201316). Septicaemia was the most common infection (14 cases in each group). Most infections were caused byStaphylococcus aureus or coagulase-negative staphylococci. The mean daily doses were: for teicoplanin, 457 mg (6.7 mg/kg); for vancomycin, 1678 mg (24.4 mg/kg); and for netilmicin 263.3 mg (3.9 mg/kg) in the teicoplanin group and 248 mg (3.8 mg/kg) in the vancomycin group. The trough levels of teicoplanin in the serum remained mostly between 7 and 10 mg/l, while more fluctuation was seen in patients receiving vancomycin. The mean trough levels of netilmicin in the serum were 1.2 (SD 0.9) mg/l in the teicoplanin group, compared with 1.7 (SD 1.4) mg/l in the vancomycin group (NS:p>0.05). The trough levels of netilmicin in the serum were often higher in the vancomycin group, resulting in decreases in the dose of netilmicin eight times in this group (25% of patients) and once in the teicoplanin group (4.2% of patients). Adjustments to the dose of vancomycin were made in six patients, due to nephrotoxicity or undesirable levels in the serum, but no adjustments to the dose were made in the teicoplanin group (p=0.032). Overall, adjustments to the dose were made to one or both study drugs in 10 patients in the vancomycin group and one in the teicoplanin group (p<0.02). Clinical and bacteriological efficacy was similar: clinical success was achieved in 80% of the patients in the teicoplanin group compared with 83% in the vancomycin group. The bacteriological response rates were 81 and 84%, respectively. Adverse events were reported in 24 patients: 7 (29%) in the teicoplanin group and 17 (53%) in the vancomycin group (p>0.05). Nephrotoxicity was reported as an adverse event in 21 patients: 6 (25%) in the teicoplanin group and 15 (47%) in the vancomycin group (p=0.09). The mean increase in the levels of creatinine in the serum at the end of therapy or up to 1 week after therapy, compared with the baseline, was significantly higher for vancomycin (56.6%), but not teicoplanin (15.3%,p<0.02). Creatinine clearance in the vancomycin group was significantly lower than baseline throughout the study period, while for teicoplanin there was no difference until the third week of treatment, and this improved again during the fourth week. It is concluded that teicoplanin is an efficacious, well-tolerated and convenient antibiotic for the treatment of Gram-positive infection in ICU patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf01713981", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "Gram-positive infections", 
      "teicoplanin group", 
      "vancomycin group", 
      "trough levels", 
      "adverse events", 
      "superior tolerability profile", 
      "mean daily doses", 
      "mean trough level", 
      "dose of vancomycin", 
      "bacteriological response rates", 
      "end of therapy", 
      "intensive care patients", 
      "acute physiological score", 
      "levels of creatinine", 
      "coagulase-negative staphylococci", 
      "Comparative Tolerability", 
      "netilmicin group", 
      "Mean SAPS", 
      "tolerability profile", 
      "bacteriological efficacy", 
      "creatinine clearance", 
      "ill patients", 
      "ICU patients", 
      "care patients", 
      "multicentre study", 
      "physiological score", 
      "common infections", 
      "daily doses", 
      "comparable efficacy", 
      "most infections", 
      "patients", 
      "clinical success", 
      "response rate", 
      "mean increase", 
      "netilmicin", 
      "fourth week", 
      "infection", 
      "study period", 
      "vancomycin", 
      "dose", 
      "third week", 
      "teicoplanin", 
      "serum", 
      "weeks", 
      "nephrotoxicity", 
      "therapy", 
      "baseline", 
      "efficacy", 
      "treatment", 
      "group", 
      "byStaphylococcus aureus", 
      "tolerability", 
      "ICU", 
      "adjustment", 
      "levels", 
      "creatinine", 
      "septicaemia", 
      "doses", 
      "clearance", 
      "drugs", 
      "total", 
      "scores", 
      "staphylococci", 
      "study", 
      "SAPS", 
      "aureus", 
      "events", 
      "paramount importance", 
      "period", 
      "decrease", 
      "differences", 
      "increase", 
      "rate", 
      "glycopeptides", 
      "profile", 
      "more fluctuations", 
      "end", 
      "success", 
      "alternative", 
      "time", 
      "importance", 
      "undesirable levels", 
      "means", 
      "order", 
      "fluctuations", 
      "netilmicin eight times", 
      "eight times"
    ], 
    "name": "Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients", 
    "pagination": "s35-s42", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027313514"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01713981"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7699155"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01713981", 
      "https://app.dimensions.ai/details/publication/pub.1027313514"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_257.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf01713981"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01713981'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01713981'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01713981'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01713981'


 

This table displays all metadata directly associated to this object as RDF triples.

267 TRIPLES      21 PREDICATES      131 URIs      123 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01713981 schema:about N020af9e8187e407d83141f4edaa7978d
2 N0b0942e1f88b4b8ea538646f08f8b132
3 N0da73069cf61499ea72fe198e290890b
4 N2929a8f2ecc6455d9fa0fc2d21722a98
5 N2c5046fe51a9427ea4e98c41be2ed7b6
6 N5ed5f5aec1b24dea9437e00c25687113
7 N64dada6eb552458c92cd2a6fa0f11964
8 N692bffcd7fe1459084d5cad7e943bfcb
9 N9935e47663fe4a9481289edb27ac1d03
10 Na21c411718124e6bbd2d57e8ba677953
11 Na643d62fc5ea4ee2abe9c12219a771cd
12 Nb9ccf3ab55e9433e8b859dfe7c080167
13 Nc4d8a25891b0425c9b73b80ea6191806
14 Nca501b97d30f4f2b9eb74e75bb891f38
15 Ncd0fffa263ee4e67842e8f40d43ae4d1
16 Ne8a743dc07f5477184ce9416c95651a9
17 Necf59ccfd66d40e0963de0b242d4f548
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N98747d72e11347268cb5d7f5cf2e45d3
21 schema:datePublished 1994-11
22 schema:datePublishedReg 1994-11-01
23 schema:description A prospective, randomized multicentre study was conducted in order to evaluate the potentially superior tolerability profile of teicoplanin plus netilmicin compared with vancomycin plus netilmicin in patients in ICUs. We considered that these glycopeptides have been shown to have comparable efficacy and that comparative tolerability is of paramount importance, particularly in severely ill patients. A total of 56 patients were enrolled into the study (36 males and 20 females). Twenty-four patients were included in the teicoplanin plus netilmicin group (15 males, 9 females: mean age 56.8 years). The mean simplified acute physiological score (SAPS) was 9.4 (range 4–20). Thirty-two patients were randomized to receive vancomycin plus netilmicin (21 males, 11 females; mean age 56.4 years). The mean SAPS was 9.3 (range 2–16). Septicaemia was the most common infection (14 cases in each group). Most infections were caused byStaphylococcus aureus or coagulase-negative staphylococci. The mean daily doses were: for teicoplanin, 457 mg (6.7 mg/kg); for vancomycin, 1678 mg (24.4 mg/kg); and for netilmicin 263.3 mg (3.9 mg/kg) in the teicoplanin group and 248 mg (3.8 mg/kg) in the vancomycin group. The trough levels of teicoplanin in the serum remained mostly between 7 and 10 mg/l, while more fluctuation was seen in patients receiving vancomycin. The mean trough levels of netilmicin in the serum were 1.2 (SD 0.9) mg/l in the teicoplanin group, compared with 1.7 (SD 1.4) mg/l in the vancomycin group (NS:p>0.05). The trough levels of netilmicin in the serum were often higher in the vancomycin group, resulting in decreases in the dose of netilmicin eight times in this group (25% of patients) and once in the teicoplanin group (4.2% of patients). Adjustments to the dose of vancomycin were made in six patients, due to nephrotoxicity or undesirable levels in the serum, but no adjustments to the dose were made in the teicoplanin group (p=0.032). Overall, adjustments to the dose were made to one or both study drugs in 10 patients in the vancomycin group and one in the teicoplanin group (p<0.02). Clinical and bacteriological efficacy was similar: clinical success was achieved in 80% of the patients in the teicoplanin group compared with 83% in the vancomycin group. The bacteriological response rates were 81 and 84%, respectively. Adverse events were reported in 24 patients: 7 (29%) in the teicoplanin group and 17 (53%) in the vancomycin group (p>0.05). Nephrotoxicity was reported as an adverse event in 21 patients: 6 (25%) in the teicoplanin group and 15 (47%) in the vancomycin group (p=0.09). The mean increase in the levels of creatinine in the serum at the end of therapy or up to 1 week after therapy, compared with the baseline, was significantly higher for vancomycin (56.6%), but not teicoplanin (15.3%,p<0.02). Creatinine clearance in the vancomycin group was significantly lower than baseline throughout the study period, while for teicoplanin there was no difference until the third week of treatment, and this improved again during the fourth week. It is concluded that teicoplanin is an efficacious, well-tolerated and convenient antibiotic for the treatment of Gram-positive infection in ICU patients.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree false
27 schema:isPartOf N1d0df080f9334a59bdbf9d5b74a4a4de
28 Ndd4671a7e4f648d9943b24afdaeafad9
29 sg:journal.1313639
30 schema:keywords Comparative Tolerability
31 Gram-positive infections
32 ICU
33 ICU patients
34 Mean SAPS
35 SAPS
36 acute physiological score
37 adjustment
38 adverse events
39 alternative
40 aureus
41 bacteriological efficacy
42 bacteriological response rates
43 baseline
44 byStaphylococcus aureus
45 care patients
46 clearance
47 clinical success
48 coagulase-negative staphylococci
49 common infections
50 comparable efficacy
51 creatinine
52 creatinine clearance
53 daily doses
54 decrease
55 differences
56 dose
57 dose of vancomycin
58 doses
59 drugs
60 efficacy
61 eight times
62 end
63 end of therapy
64 events
65 fluctuations
66 fourth week
67 glycopeptides
68 group
69 ill patients
70 importance
71 increase
72 infection
73 intensive care patients
74 levels
75 levels of creatinine
76 mean daily doses
77 mean increase
78 mean trough level
79 means
80 more fluctuations
81 most infections
82 multicentre study
83 nephrotoxicity
84 netilmicin
85 netilmicin eight times
86 netilmicin group
87 order
88 paramount importance
89 patients
90 period
91 physiological score
92 profile
93 rate
94 response rate
95 scores
96 septicaemia
97 serum
98 staphylococci
99 study
100 study period
101 success
102 superior tolerability profile
103 teicoplanin
104 teicoplanin group
105 therapy
106 third week
107 time
108 tolerability
109 tolerability profile
110 total
111 treatment
112 trough levels
113 undesirable levels
114 vancomycin
115 vancomycin group
116 weeks
117 schema:name Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients
118 schema:pagination s35-s42
119 schema:productId Nbf513b417b684ee3bd7a9e940a099af8
120 Nd096bf47f0c847dca50bfd694757f8c0
121 Nd8f99660c18845438c03e8bcb36733e0
122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027313514
123 https://doi.org/10.1007/bf01713981
124 schema:sdDatePublished 2022-01-01T18:07
125 schema:sdLicense https://scigraph.springernature.com/explorer/license/
126 schema:sdPublisher Na8b2cc751709496a8342543b16ea505d
127 schema:url https://doi.org/10.1007/bf01713981
128 sgo:license sg:explorer/license/
129 sgo:sdDataset articles
130 rdf:type schema:ScholarlyArticle
131 N020af9e8187e407d83141f4edaa7978d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Middle Aged
133 rdf:type schema:DefinedTerm
134 N0b0942e1f88b4b8ea538646f08f8b132 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Drug Monitoring
136 rdf:type schema:DefinedTerm
137 N0da73069cf61499ea72fe198e290890b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Aged
139 rdf:type schema:DefinedTerm
140 N1d0df080f9334a59bdbf9d5b74a4a4de schema:volumeNumber 20
141 rdf:type schema:PublicationVolume
142 N2929a8f2ecc6455d9fa0fc2d21722a98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Critical Care
144 rdf:type schema:DefinedTerm
145 N2c5046fe51a9427ea4e98c41be2ed7b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Gram-Positive Bacterial Infections
147 rdf:type schema:DefinedTerm
148 N5ed5f5aec1b24dea9437e00c25687113 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Humans
150 rdf:type schema:DefinedTerm
151 N64dada6eb552458c92cd2a6fa0f11964 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Drug Therapy, Combination
153 rdf:type schema:DefinedTerm
154 N692bffcd7fe1459084d5cad7e943bfcb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Kidney Diseases
156 rdf:type schema:DefinedTerm
157 N78fbcca1f0ac4a18bb6f3c766973f4c8 rdf:first sg:person.0741664152.85
158 rdf:rest N93d76abb71d54756b9f8f2b7d8ed698b
159 N93d76abb71d54756b9f8f2b7d8ed698b rdf:first sg:person.0610744222.10
160 rdf:rest rdf:nil
161 N98747d72e11347268cb5d7f5cf2e45d3 rdf:first sg:person.01270350653.48
162 rdf:rest Nc13823ed7efc46ef89eb47f67c013fbc
163 N9935e47663fe4a9481289edb27ac1d03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Male
165 rdf:type schema:DefinedTerm
166 Na21c411718124e6bbd2d57e8ba677953 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Cross Infection
168 rdf:type schema:DefinedTerm
169 Na643d62fc5ea4ee2abe9c12219a771cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Vancomycin
171 rdf:type schema:DefinedTerm
172 Na8b2cc751709496a8342543b16ea505d schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 Nb9ccf3ab55e9433e8b859dfe7c080167 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Aged, 80 and over
176 rdf:type schema:DefinedTerm
177 Nbf513b417b684ee3bd7a9e940a099af8 schema:name dimensions_id
178 schema:value pub.1027313514
179 rdf:type schema:PropertyValue
180 Nc13823ed7efc46ef89eb47f67c013fbc rdf:first sg:person.01006233511.50
181 rdf:rest Nfb00abf54f7a4b1594ae434df3d09977
182 Nc4d8a25891b0425c9b73b80ea6191806 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Prospective Studies
184 rdf:type schema:DefinedTerm
185 Nca501b97d30f4f2b9eb74e75bb891f38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Netilmicin
187 rdf:type schema:DefinedTerm
188 Ncd0fffa263ee4e67842e8f40d43ae4d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Teicoplanin
190 rdf:type schema:DefinedTerm
191 Nd096bf47f0c847dca50bfd694757f8c0 schema:name doi
192 schema:value 10.1007/bf01713981
193 rdf:type schema:PropertyValue
194 Nd8f99660c18845438c03e8bcb36733e0 schema:name pubmed_id
195 schema:value 7699155
196 rdf:type schema:PropertyValue
197 Ndd4671a7e4f648d9943b24afdaeafad9 schema:issueNumber Suppl 4
198 rdf:type schema:PublicationIssue
199 Ndde3b02e22ab4a24be0d6fdddb3b9581 rdf:first sg:person.07631560136.36
200 rdf:rest N78fbcca1f0ac4a18bb6f3c766973f4c8
201 Ne8a743dc07f5477184ce9416c95651a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Adult
203 rdf:type schema:DefinedTerm
204 Necf59ccfd66d40e0963de0b242d4f548 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Female
206 rdf:type schema:DefinedTerm
207 Nfb00abf54f7a4b1594ae434df3d09977 rdf:first sg:person.01317726721.21
208 rdf:rest Ndde3b02e22ab4a24be0d6fdddb3b9581
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
213 schema:name Clinical Sciences
214 rdf:type schema:DefinedTerm
215 sg:journal.1313639 schema:issn 0342-4642
216 1432-1238
217 schema:name Intensive Care Medicine
218 schema:publisher Springer Nature
219 rdf:type schema:Periodical
220 sg:person.01006233511.50 schema:affiliation grid-institutes:None
221 schema:familyName Harding
222 schema:givenName I.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006233511.50
224 rdf:type schema:Person
225 sg:person.01270350653.48 schema:affiliation grid-institutes:grid.411149.8
226 schema:familyName Charbonneau
227 schema:givenName P.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270350653.48
229 rdf:type schema:Person
230 sg:person.01317726721.21 schema:affiliation grid-institutes:grid.417993.1
231 schema:familyName Garaud
232 schema:givenName J. J.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317726721.21
234 rdf:type schema:Person
235 sg:person.0610744222.10 schema:affiliation grid-institutes:grid.411119.d
236 schema:familyName Domart
237 schema:givenName Y.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610744222.10
239 rdf:type schema:Person
240 sg:person.0741664152.85 schema:affiliation grid-institutes:grid.411784.f
241 schema:familyName Brunet
242 schema:givenName F.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741664152.85
244 rdf:type schema:Person
245 sg:person.07631560136.36 schema:affiliation grid-institutes:grid.42399.35
246 schema:familyName Aubertin
247 schema:givenName J.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07631560136.36
249 rdf:type schema:Person
250 grid-institutes:None schema:alternateName Thackelay's Ltd, Horton, SN10 3NB, Devizes, Wiltshire, UK
251 schema:name Thackelay's Ltd, Horton, SN10 3NB, Devizes, Wiltshire, UK
252 rdf:type schema:Organization
253 grid-institutes:grid.411119.d schema:alternateName University Hospital Bichat, Paris, France
254 schema:name University Hospital Bichat, Paris, France
255 rdf:type schema:Organization
256 grid-institutes:grid.411149.8 schema:alternateName Service de Réanimation Medicale et de Maladies Infectieuses, University Hospital, Avenue de la Côte de Nacre, F-14033, Caen, CEDEX, France
257 schema:name Service de Réanimation Medicale et de Maladies Infectieuses, University Hospital, Avenue de la Côte de Nacre, F-14033, Caen, CEDEX, France
258 rdf:type schema:Organization
259 grid-institutes:grid.411784.f schema:alternateName University Hospital Cochin, Paris, France
260 schema:name University Hospital Cochin, Paris, France
261 rdf:type schema:Organization
262 grid-institutes:grid.417993.1 schema:alternateName Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, New Jersey, USA
263 schema:name Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, New Jersey, USA
264 rdf:type schema:Organization
265 grid-institutes:grid.42399.35 schema:alternateName University Hospital, Bordeaux, France
266 schema:name University Hospital, Bordeaux, France
267 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...